Arima Genomics

Arima Genomics develops DNA-based cancer diagnostics that bring genomic sequence and structure together to reveal more of what drives disease, creating new opportunities to guide therapy and bring patients closer to the right treatment. The company's pioneering work in 3D genome science enables detection of structural events that change how cancer genes function, including fusions and rearrangements, enhancer hijacking, extrachromosomal DNA (ecDNA), and other mechanisms that can affect therapy selection. Arima's technology is based on Hi-C sequencing, which combines proximity ligation with short-read DNA sequencing and a proprietary probabilistic algorithm for haplotype assembly (called HaploSeq), enabling genome-scale phasing or haplotyping of DNA variants. By connecting genome structure with DNA sequence, Arima can expose hidden drivers, uncover new biomarker opportunities, and create new paths for clinical and therapeutic development. The company's clinical testing brand, Aventa, brings Hi-C sequencing technology into cancer care through tests designed for routine FFPE samples, including Aventa FusionPlus (detecting clinically relevant fusions and rearrangements that can guide therapy selection or support diagnosis in solid tumors) and Aventa Lymphoma (identifying clinically relevant rearrangements that can inform diagnosis, classification, prognosis, and treatment planning). Arima also engages in biopharma partnerships to connect structural cancer drivers to therapeutic opportunity, identifying biomarker-defined patient populations and informing development strategy, and collaborates with leading scientists on translational science studying cancer-driving structural mechanisms. Arima differentiates itself through its unique 3D genome science approach that captures structural information conventional sequencing approaches were not built to see, its tissue-efficient assay working with routine FFPE samples, and its ability to detect structural events like enhancer hijacking and ecDNA that other methods miss. Founded in 2015 and headquartered in San Diego, United States, Arima Genomics has raised approximately $29 million in a Series C round backed by Agilent, Co-win Ventures, Vectr Ventures, Berkeley Catalyst Fund, Tech Coast Angels, Ladder Ventures, HHS, Illumina Ventures, Bioworld Ventures, and Phase Two Ventures.